A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area

por Hussein, Jemal, Zewdie, Martha, Yamuah, Lawrence, Bedru, Ahmed, Abebe, Markos, Dagnew, Alemnew F., Chanyalew, Menberework, Yohannes, Asfawesen G., Ahmed, Jemal, Engers, Howard, Doherty, T. Mark, Bang, Peter, Kromann, Ingrid, Hoff, Søren T., Aseffa, Abraham
Publicado 2018